# "Sustainable Pharmaceutical Packaging Market, till 2035"

Dissertation submitted in partial fulfilment of the requirements for the award of the degree of

## **Masters of Science in Biotechnology**

By

Sanskriti Sauhta

(225111016)

Under the Guidance of

Ms. Rupanshi Sharma

(Roots Analysis Pvt. Ltd.)

and

Dr. Ashok Kumar Nadda (JUIT)

To



DEPARTMENT OF BIOTECHNOLOGY AND BIOINFORMATICS

JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY

WAKNAGHAT, SOLAN- 173234

HIMACHAL PRADESH, INDIA

# **DISCLAIMER**

The information presented in this Dissertation is intended solely for academic evaluation as part of the submission requirements for the university program. The university assures that the content will not be used for any other purpose without explicit consent from the author. Any unauthorized use, reproduction, distribution, or disclosure of this material is strictly prohibited. The university is liable for any consequences arising from the use of this information beyond academic evaluation.

Copyright © Roots Analysis Private Limited

#### **DECLARATION**

I hereby declare that the work presented in this report entitled "Sustainable Pharmaceutical Packaging Market, till 2035" for partial fulfilment for the award of degree of Master of Science in Biotechnology submitted in the Department of Biotechnology & Bioinformatics, Jaypee University of Information Technology, Waknaghat is an authentic record of my work carried out at Roots Analysis Pvt. Ltd. over a period from January 2024 to June 2024 under the guidance of Rupanshi Sharma (Project Manager) and Dr. Ashok Kumar Nadda (Assistant Professor, BT&BI, JUIT).

The matter embodied in the report has not been submitted for the award of any other degree or diploma.



(Student Signature)

Sanskriti Sauhta

#### 225111016

This is to certify that the above statement made by the candidate is true to the best of my knowledge.

(Supervisor Signature)

Supervisor Name: Dr. Ashok Kumar Nadda

#### Assistant Professor,

Biotechnology & Bioinformatics, JUIT

Dated: 17 May, 2024

Certified that the above statement made by the student is correct to the best of our knowledge and belief. Roots Analysis owns the copyright of the findings presented in this report. Under no circumstances should this information be shared with other third parties without the prior consent of the company. Luganshi

Rupanshi Sharma

**Project Manager** 

Roots Analysis Pvt. Ltd.

## SUPERVISOR'S CERTIFICATE

This is to certify that the work reported in the Dissertation entitled 'Sustainable Pharmaceutical Packaging Market, till 2035'submitted by Sanskriti Sauhta for partial fulfilment for the award of degree of Masters of Science in Biotechnology from Jaypee University of Information & Technology, Waknaghat has been carried out under my supervision. This report was not submitted to any other University or Institute in full or in part for the award of any other degree, certificate or other titles.

Luganshi

Dr. Ashok Kumar Nadda (Guide)

**Assistant Professor,** 

Jaypee University of Information Technology

Rupanshi Sharma Project Manager

Roots Analysis Pvt. Ltd

**ACKNOWLEDGEMENT** 

I would like to express my sincere gratitude to the faculty of Jaypee University of Information

Technology, Waknaghat, Himachal Pradesh, for providing the opportunity to pursue new

opportunities and enhance my skills in the field of biotechnology.

I express my sincere gratitude to Mr. Gaurav Chaudhary for providing the opportunity to work at

Roots Analysis Pvt. Ltd, Mohali (Punjab).

I am thankful to Ms. Rupanshi Sharma for providing her constant support, cooperation, and

motivation during this period and to other team members who provided their valuable suggestions. I

would also like to express my sincere gratitude to Ms. Dakshita Dhawan, whose crucial contributions

were essential in shaping the outcomes of this project.

Moreover, I also want to convey my heartfelt thanks to Ms. Mansi Bhanwal and Ms. Manika Goyal

for their continuous support, assistance, and guidance throughout my project.

I am profoundly thankful to my parents for their inspiration, constant guidance, and motivation at all

stages of my life.

Sanskriti Sauhta

225111016

5

# **TABLE OF CONTENT**

| S.No. | Торіс                                | Page No. |
|-------|--------------------------------------|----------|
| 1.    | About Roots Analysis Private Limited | 8-10     |
| 2.    | Abstract                             | 11       |
| 3.    | Introduction                         | 12-20    |
| 4.    | Market Landscape                     | 21-22    |
| 5.    | Sample Company Profiles              | 23-28    |
| 6.    | Partnerships and Collaborations      | 29-30    |
| 7.    | Funding and Investments              | 31-33    |
| 8.    | Interview Contact List               | 34-36    |
| 9.    | Conclusion                           | 37       |
| 10.   | References                           | 38-39    |

# **TABLE OF FIGURES**

| S.No. | Description  | Page No. |
|-------|--|----------|
| 1.    | Steps Involved in Pharmaceutical Aseptic Packaging           | 13       |
| 2.    | Advantages of Pharmaceutical Packaging                       | 14       |
| 3.    | Types of Pharmaceutical Packaging                            | 14       |
| 4.    | Drawbacks of Conventional Pharmaceutical Packaging Materials | 16       |
| 5.    | Raw Materials for Packaging                                  | 17       |
| 6.    | ISO Standards for Pharmaceutical Packaging                   | 18       |
| 7.    | Advantages of Sustainable Pharmaceutical Packaging Materials | 18       |
| 8.    | Limitations of Sustainable Pharmaceutical Packaging Material | 19       |
| 9.    | Sustainable packaging providers Database Glimpse             | 22       |
| 10.   | Sustainable packaging providers Analysis Glimpse             | 22       |
| 11.   | Company A: Annual Revenues, FY2019 – H1 FY2024 (GBP Million) | 26       |
| 12.   | Partnerships and Collaborations Database Glimpse             | 29       |
| 13.   | Partnerships and Collaborations Analysis Glimpse             | 30       |
| 14.   | Funding and Investments Database Glimpse                     | 32       |
| 15.   | Funding and Investments Analysis Glimpse                     | 32       |

# **About Roots Analysis Private Limited**

**Roots Analysis Pvt. Ltd.** is a business research and consulting firm which specializes in providing in-depth business research and consulting services for the pharmaceutical industry. Focused on providing an informed and impartial view on key challenges facing the industry, the research is primarily driven by an in-depth analysis covering the following parameters:

- Research and development
- Existing market landscape
- Future Commercial potential
- Regulatory concerns
- Regional growth drivers
- Risks and opportunities

The firm specializes in analyzing areas which have lacked quality research so far or require more focused understanding within the broader industry. Apart from writing reports on identified areas, the company also provides bespoke research / consulting services dedicated to serve our clients in the best possible way.

The business reports highlight trends ranging from commercial success / potential, technological developments and outlook built around opportunities and threats. The company majorly focus on areas spanning the following domains:

- Therapeutic segments
- Emerging technologies
- Medical devices
- Drug Delivery
- Clinical Trials

### **Research Methodology**

Most of the data presented in this report has been gathered via secondary and primary research. We have conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

- Company's Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Industry analysts' views
- Research articles; Blogs; Press articles
- Company website

## Work Program

While the focus has been on providing a comprehensive view on the ongoing technological innovations, the report "Sustainable Pharmaceutical Packaging Market, till 2035" also provides an independent view on research and development and future commercial potential emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

The course of my internship at Roots Analysis started on 2<sup>nd</sup> January 2024. I was involved in a project, on which I worked for 5 months. The training program is structured as follows:

The main objective of this report is to build a comprehensive database of Sustainable packaging providers along with type of services / products offered by them, funding analysis and the likely growth of partnership activity in this domain, by using available

data of various companies on company's website, LinkedIn profiles and other publicly available sources.

- Further, an analysis around this information will be presented to provide a high-level quick overview of the ongoing activity in this domain.
- Collection of company specific data.
- Introduction chapter on sustainable pharmaceutical packaging, emerging needs and various advantages associated with it.
- Detailed profiling of key stakeholders in this domain.
- Capturing partnership and funding database.
- Screening and analysis of related partnerships and funding.
- Finding the contact details of the prominent speakers in conferences and contacts of the key individuals belonging to players in this domain.
- Concluding the report with its insights, learnings, outcomes and the future scope.

### **Abstract**

The project "Sustainable Pharmaceutical Packaging Market, till 2035" broadly features a detailed assessment of players engaged in offering products and / or services for sustainable, biodegradable, and eco-friendly packaging in the healthcare sector. The study offers a comprehensive analysis of the main factors and trends associated with this field.

The report provides a general overview on the pharmaceutical packaging, the different types of pharmaceutical packaging and various sustainable pharmaceutical packaging solutions / services that are currently available in the market. The research also report provides a thorough study on the present market landscape of sustainable packaging providers that are engaged in providing products and /or services in this domain. Further, the report also provides a detailed analysis of the several partnerships and fundings that have been inked / raised by sustainable packaging providers in the healthcare sector. Extensive primary and secondary research was conducted to collect relevant information on the topic.

Upon finishing the study, a database was created in excel featuring information on more than 122 sustainable packaging providers, along with the product / services information offered by them. It includes an in-depth analysis of these players based on their establishment year, location of headquarters, company size, type of offerings, ISO certifications accredited, type of eco-friendly packaging, origin of packaging material, type of packaging material used, type of packaging and packaging applications. Company specific details captured, includes company's establishment year, employee strength, location of headquarters, and leading players based on the number of products they offer. Furthermore, an analysis was conducted to depict the current status of the industry.

# **Chapter 1**

### Introduction

## **Chapter Overview**


Packaging is the process of enclosing a product in a container in order to protect and store it. Packaging plays a significant role in maintaining the integrity and strength of a product within the pharmaceutical industry. The type of raw material utilized for packaging highly depends on the type of product / drug enclosed. Glass, plastic, metals, cardboard and wood are some of the most commonly used raw materials for pharmaceutical packaging. However, a huge amount of waste is generated due to these conventional raw materials primarily due to their inability to decompose naturally. It is worth highlighting that over 500 million tonnes of waste is generated through pharmaceutical packaging globally. [1] Further, the global demand for pharmaceutical products is continuously increasing, imposing a burden on the environment. Therefore, there is a menacing need to shift towards alternative sustainable, eco-friendly and biodegradable raw materials for packaging. [2], [3]

The adoption of recycled paper, plastic, and cardboard has emerged as a promising substitute for traditional pharmaceutical packaging materials. These materials have helped in optimizing both cost and sustainability of the process. Further, these materials have also been formulated to decompose naturally, leaving no harmful residues. This has helped in substantially lowering the environmental impact, when compared to other traditional petroleum plastics.[4] This chapter provides a brief overview of the pharmaceutical packaging, along with their advantages. Further, we have highlighted the different types of pharmaceutical packaging and the need for Sustainable Pharmaceutical Packaging materials. In addition, we have provided information on various regulatory frameworks required in the pharmaceutical packaging industry, along with the benefits and limitations of using sustainable / biodegradable packaging materials for pharmaceutical products.

#### **Pharmaceutical Packaging**

Pharmaceutical packaging materials such as vials, blisters, stoppers, cartridges and many more, which are required for filling, sealing, packaging and labelling of the drugs. The primary requisite of pharmaceutical packaging is that these should be user friendly, inert and compatible with the different dosage forms. In order to achieve this, the pharmaceutical packaging processes go through various checkpoints and regulatory guidelines at each step.[5], [6], [7]

Figure 1 Steps Involved in Pharmaceutical Aseptic Packaging




\_\_\_\_

Steps involved in the pharmaceutical aseptic packaging process include:

- Container Production: It includes the production of containers such as bottles, syringes, vials, and bags at the manufacturing facility to proceed with the pharmaceutical packaging process.
- **Transportation:** After the successful production of containers, they are transported to another facility where the fill-finishing process takes place.
- Container Sterilization: All the containers are sterilized as a fundamental operation to destroy the micro-organisms present in it and prevent the contamination of the product.
- Aseptic Filling: It involves filling commercially sterilized products into containers that have been pre-sterilized.
- **Stoppering and Capping:** Post filling all the containers, the drug products are capped and sealed aseptically.
- **Freeze Drying:** It is done for heat-sensitive drugs in order to store them at room temperature for a longer period of time.

Pharmaceutical packaging plays a significant role in shipping sensitive and tightly regulated pharmaceutical products. Figure 2 presents a pictorial summary of the various advantages associated with pharmaceutical packaging. [9]

Figure 2 Advantages of Pharmaceutical Packaging



Roots Analysis

#### **Types of Pharmaceutical Packaging**

There are three categories of packaging: primary, secondary, and tertiary. Figure 3 displays the various types of pharmaceutical packaging. [10]

Figure 3Types of Pharmaceutical Packaging



Roots Analysis

Additional details on the various types of packaging are outlined below:

- Primary packaging: It pertains to the material that is in direct contact with the drug product, which directly affects its shelf life. Majority of the oral solid dosage forms are primarily being packaged in blister packs, sachets and plastic bottles. Further, vials, ampoules and bottles made of plastic or glass are used for primary packaging of liquids (injectables / orals). Apart from the aforementioned types of primary packaging, foil packaging, composed of metals such as aluminium and stainless steel, is extensively utilized by medical companies and laboratories to securely transport medical devices and samples.[11]
- Secondary packaging: Once the drug is packed in a primary package, another packaging layer is required for its safety, termed as secondary packaging. It consists of printed material (*label*) containing all information about the active and inactive ingredients used in the preparation. Along with this it also presents the information regarding dosage form, dosing schedule, manufacturer's name and address, marketing details of the company, and warning (*if any*). While providing additional protection to the drug product, secondary packaging is also used to ameliorate the attractiveness and brand image of the manufacturer. The most commonly used materials for secondary packing include paper, cardboard and plastic.[12]
- **Tertiary packaging:** When transporting pharmaceuticals in bulk from one location to another, an additional protective layer known as tertiary packaging is essential. Materials for the preparation of tertiary packaging include cardboard, pasteboard and wood.[13]

#### **Need For Sustainable Pharmaceutical Packaging**

Globally, only 2% of plastic packaging materials are recycled, while others are either incinerated or dumped into landfills and water bodies. Further, it is important to mention that 30% of the plastic packaging materials are either too complex or too small to recycle; examples include sachets and wrappers resulting in a negative impact on the environment. [14] These packaging materials on the environment are a major concern, hence stirred an alarming need for research in this domain.

Some of the major drawbacks of conventional packaging materials include dependency on fossil fuels, its single-use nature, its inability to biodegrade, chemical leaching and negative public perception. Figure 4 represents the pictorial representation of these drawbacks. [15]

Figure.4 Drawbacks of Conventional Pharmaceutical Packaging Materials



Roots Analysis

#### **Sustainable Pharmaceutical Packaging Solutions**

Sustainability word originated from the Latin word *sustinere*, which means to hold or support. Sustainable packaging is packaging that is safe for both individuals and the environment, while meeting the cost and manufacturing efficiency. Over time, to reduce the impact on environment, many companies and individuals are shifting towards sustainable materials for packaging. In fact, researchers are actively involved in designing novel bio-based raw materials, in order to achieve the desired strength and integrity, along with maintaining the sustainability of the product. In addition, these raw materials are harvested in a way to reduce the consumption of natural resources. Several monomaterials, such as paper, plastic, glass, fabric or metal are also being used in production processes to facilitate the separation of components while recycling.[16], [17]

Moreover, pharmaceutical companies are increasingly focusing on streamlining various packaging operations, which can contribute to reduced raw material and energy consumption. Various steps are being taken to streamline the packaging to make it more sustainable, for instance in the blister packs,

the amount of heat applied is reduced in order to conserve energy and water consumption. Furthermore, companies are continuously tracking the supply chain to optimize manufacturing output and product distribution, thereby minimizing overproduction. As a result, there will be a reduction in energy consumption associated with storing and transporting excess goods.[18]

Figure 5 presents information on the raw materials used in various types of packaging. [19]




Figure 5 Raw Materials for Packaging

#### **Regulatory Framework**

Pharmaceutical industry is one of the highly regulated industries in the world, with stringent controls across each step of development and production, to maintain quality standards and to ensure safety and effectiveness of pharmaceutical products to the patients. Use of natural or plant-based materials as primary packaging is often associated with the potential risk of its interactions with the drug product, which can lead to serious health issues. To avoid such instances, various guidelines have been issued by regulatory authorities. The first and most common is the guideline for good manufacturing practices (GMP), which ensures the proper manufacturing, maintenance, labeling and storage of products. Further, international organization for standardization (ISO) has been established to enforce safe packaging and storage of pharmaceutical agents.[20]

Figure 6 presents the information on various ISO standards related to pharmaceutical packaging.[21]





Roots Analysis

Roots Analysis

#### **Advantages of Sustainable Pharmaceutical Packaging Materials**

Sustainable Pharmaceutical Packaging materials have a wide array of advantages primarily due to their ability to decompose naturally in the environment and reduce the consumption of resources. Figure 7 presents some advantages associated with Sustainable Pharmaceutical Packaging materials in the pharmaceutical industry.[22], [23]

Figure 7Advantages of Sustainable Pharmaceutical Packaging Materials



#### **Limitation of Sustainable Pharmaceutical Packaging Materials**

Despite the multiple benefits offered by Sustainable Pharmaceutical Packaging, there are certain limitations associated with it. Figure 8 presents the constraints linked to Sustainable Pharmaceutical Packaging materials in the pharmaceutical industry.[24]

Figure 8Limitations of Sustainable Pharmaceutical Packaging Materials



Major challenge associated with using bio-based raw materials is its potential to interact with the packed drug or other materials



It is difficult to maintain sterile and vapour-free environment while using green packaging materials



Using sustainable packaging materials can increase the cost of the packing which can affect the overall cost of the product



Sustainable materials require expert handling and specialized machinery to be able to cast the material into desired shape and size



Sustainable packaging materials lack durability and strength as compared to conventional petroleum plastics

Roots Analysis

#### **Future Perspectives**

In recent years, the pharmaceutical industry has witnessed significant developments related to biodegradable / recyclable materials (*potential alternatives to plastics*); some of these are being widely used for packaging purposes. One such material is plastic made from sugarcane, which is biodegradable in nature.[25] This product has shown promising results, in terms of strength and majority of its properties, such as non-reactivity and robustness, as compared to traditional petroleum plastic. Further, other plastic alternatives, such as polylactic acid obtained from corn starch, sugarcane, and cassava, can serve as excellent materials for sustainable pharmaceutical packaging.

These novel sustainable pharmaceutical packaging materials hold a promise to eliminate the unprecedented issue of environmental degradation in the pharmaceutical industry. This will eventually lead to a sustainable future not only in the pharmaceutical domain but many other industries. Further, we believe that with increasing awareness related to the benefits of Sustainable Pharmaceutical Packaging, this market segment is expected to witness increased adoption in the upcoming years.

### MARKET LANDSCAPE

#### **Chapter Overview**


Comprehensive research is conducted to create a database that includes various parameters are decided to capture information for various sustainable packaging providers and their respective products. The database developed within this project includes close to 122 companies providing multiple Sustainable Pharmaceutical Packaging products / services along with parameters like:

- Provider's Year of establishment
- Location of headquarters
- Number of employees
- Company size
- Type of offerings (Products, Services)
- ISO Certifications
- Type of Eco-friendly Packaging (*Reusable*, *Biodegradable*, *Recyclable*)
- Origin of Packaging Material (*Natural, Synthetic*)
- Type of Packaging Material Used
- Type of Packaging (*Primary, Secondary, Tertiary*)
- Type of Packaging Containers
- Packaging Applications (storage containers, pharmaceutical laminates, closures, drug delivery devices, surgical devices, eutectic plates, cooling bags and dosage cups)

# **Sustainable Packaging Providers: Database**


The database created for companies offering sustainable pharmaceutical packaging products / services is curated by extensive primary and secondary market research through various available sources. Figure 9 and 10 provides a preview of the database and analysis conducted using several parameters.

Figure 9 Sustainable Packaging Providers Database Glimpse



Source: Roots Analysis

Figure 10 Sustainable Packaging Providers Analysis Glimpse



Source: Roots Analysis

Information including additional sustainable packaging providers has been incorporated into the project report which cannot be disclosed due to confidentiality reasons.

## SAMPLE COMPANY PROFILES

#### **Chapter Overview**

The chapter presents profiles of prominent players (*shortlisted based on company size of more than 1,000 employees, offering products or services based on all the four types of eco-friendly packaging (reusable, biodegradable, reducible and recyclable)*) engaged in offering services or products for sustainable, biodegradable and eco-friendly packaging for the healthcare sector. Each profile includes the following sections:

- Company Overview: This section provides a brief company overview, including details such as its year of establishment, headquarters location, employee count, company type, and leadership team.
- **Financial Information** (*if available*): This section includes information on the financial revenues of the company.
- Sustainable Pharmaceutical Packaging Offerings: This section includes detailed information on various products / services offered by the company related to sustainable, biodegradable and eco-friendly packaging (based on the company website and / or other publicly available information).

**Recent Developments and Future Outlook:** This section provides information on the initiatives / recent developments related to sustainable, biodegradable and eco-friendly packaging and strategies that, we believe, (based on the latest press releases by the company and / or other publicly available information) the company may adopt in order to drive its growth, in the coming future.

Table 1 lists the companies (organized alphabetically) highlighted in this chapter.

Table 1 Sustainable Packaging Providers: List of Companies Profiled

| S. No. | Company   | YoE         | LoH (State / City, Country) | LoH (Region)  |
|--------|-----------|-------------|-----------------------------|---------------|
| 1      | Company A | 1963        | Pennsylvania, US            | North America |
| 2      | XX        | Sample Text | Sample Text                 | Sample Text   |
| 3      | XX        | Sample Text | Sample Text                 | Sample Text   |
| 4      | XX        | Sample Text | Sample Text                 | Sample Text   |
| 5      | XX        | Sample Text | Sample Text                 | Sample Text   |
| 6      | XX        | Sample Text | Sample Text                 | Sample Text   |
| 7      | Syntegon  | 1969        | Waiblingen, Germany         | Europe        |

Abbreviation: YoE: Year of Establishment, LoH: Location of Headquarters

Source: Roots Analysis

#### **COMPANY A**

## **Company Overview**

Company A is a UK-based company that is engaged in providing innovative packaging solutions, paper-based products as well as recycling services across the world. The company is dedicated towards sustainability and incorporating a circular economy through its various supply chains. Further, it is worth highlighting that the company is partnering with other eminent players with an intent to reduce complexity involved in Sustainable Pharmaceutical Packaging and minimize the environmental impact.

Table 2 presents the overview of Company A.

Table 2 Company A: Overview


| Key Parameters        | Description |
|-----------------------|-------------|
| Year of Establishment | XX          |
| Headquarters          | XX          |
| Number of Employees   | XX          |
| Leadership Team       | XX          |

Source: Roots Analysis

#### **Financial Information**

Figure 12 showcases the company's revenue for the period spanning from FY 2019 to the first half of FY 2024.

Figure 12 Company A: Annual Revenues, FY2019 - H1 FY2024(GBP Million)



Source: Roots Analysis

# **Sustainable Pharmaceutical Packaging Offerings**

Table 3 provides information on the Sustainable Pharmaceutical Packaging offerings of Company A.

Table 3 Company A: Sustainable Pharmaceutical Packaging Offerings

| Key Parameters                 | Sustainable Pharmaceutical Packaging Offerings   |
|--------------------------------|--|
| Type of Eco-friendly Packaging | • XX<br>• XX   |
| Origin of Packaging Material   | <ul> <li>XX</li> <li>XX</li> <li>XX</li> <li>XX</li> <li>XX</li> <li>XX</li> <li>XX</li> </ul> |
| Packaging Material Used        | XX   |
| Packaging Applications         | • XX<br>• XX<br>• XX   |

Source: Roots Analysis

# **Recent Developments and Future Outlook**

Table 4 outlines the recent developments and strategies that we anticipate Company A will implement to stimulate future growth.

Table 4 Company A: Recent Developments and Future Outlook

| Strategic Ini  | tiatives   | Recent / Past Trends          | Future Outlook |
|--|--|-------------------------------|----------------|
|  |  | August 2023                   |                |
|  |  | Sample Text                   |                |
|  | Attending conferences and                                  | March 2022                    | Samula Taut    |
|  | other events to<br>increase company<br>visibility          | Sample Text                   | Sample Text    |
|  | Visionity  | January 2022                  |                |
|  |  | Sample Text                   |                |
|  |  | September 2023<br>Sample Text |                |
|  | Appointing key personnel to strengthen the Management Team | February 2023                 |                |
| _0_  |  | Sample Text                   |                |
| <b>≛</b> ≡   |  | August 2022                   | Sample Text    |
|  |  | Sample Text                   |                |
|  |  | February 2022                 |                |
|  |  | Sample Text                   |                |
|  |  | October 2022                  |                |
|  |  | Sample Text                   |                |
| A CONTRACTOR OF THE PARTY OF TH | Entering into<br>Strategic<br>Collaborations               | September 2022<br>Same Text   | Sample Text    |
|  |  | August 2022                   |                |
|  |  | Sample Text                   |                |
|  |  |                               |                |

| Strategic Initiatives | Recent / Past Trends | Future Outlook |
|-----------------------|----------------------|----------------|
|                       | January 2022         |                |
|                       | Sample Text          |                |

Source: Roots Analysis

Comprehensive profiles of additional sustainable packaging providers are featured in the project report but cannot be disclosed for confidentiality reasons.

#### PARTNERSHIPS AND COLLABORATIONS

#### **Chapter Overview**

We came across several sustainable packaging providers during our research, that have entered into various partnerships with different stakeholders in the industry to expand their product / service portfolios, gain additional capabilities and more visibility in this domain. This chapter provides an overview of the partnering activity reported in this domain, during the period 2019-2024 (*till February*). Additionally, this chapter offers information on various partnership models that have been utilized by the industry players in recent years. The partnership instances captured during our research were analyzed across several parameters, such as partnership year, partnership type, type of partner and type of eco-friendly packaging. Additionally, we have identified the most active players within the domain (*in terms of number of partnerships signed*) along with geographical distribution of the partnership activity.

## Partnerships and Collaborations: Input Database

Figure 13 and 14 provides the collated data and analysis of various partnerships inked between the stakeholders engaged in this domain.

Figure 13 Partnerships and Collaborations Database Glimpse





Figure 14 Partnerships and Collaborations Analysis Glimpse



Source: Roots Analysis

The project report contains a thorough analysis of all the partnerships and collaborations, which cannot be revealed due to confidentiality reasons.

#### FUNDING AND INVESTMENTS

#### **Chapter Overview**

Over time, financial support from angel investors, venture capitalists, public and private funding programs, and regulatory bodies has enabled Sustainable packaging providers to strengthen their research and development activities in the Sustainable Pharmaceutical Packaging sector. This chapter examines the capital investments made in companies involved in developing Sustainable Pharmaceutical Packaging products and services, providing an overview of the evolution of investment activity in the overall market. Further, this chapter provides details on funding instances (*in reverse chronological order*) reported by companies providing Sustainable Pharmaceutical Packaging services / products, along with the information on their year of establishment, location of headquarters, company size, type of funding, month and year of funding, amount invested (USD million) and lead investors (*wherever applicable*).

It is important to mention that the information presented in the chapter is completely factual and should not be misconstrued as a recommendation regarding any of the companies / products mentioned within. The funding instances presented in the following sections were identified from company websites, press releases and other publicly available databases.

# **Funding Models**

For the purpose of this analysis, we have examined various methods through which a company may secure financing. These include:


- Debt Financing: In debt financing, a company secures financing from a or an investor through venture debt and is obligated to repay the principal amount along with interest, regardless of its profitability.
- Grant / Award: Grants and awards are provided by government and non-government agencies like the National Institutes of Health and the Bill and Melinda Gates Foundation. Although grants typically involve smaller amounts compared to other funding sources, they support early-stage research efforts for small companies.
- **Private Placement:** Private placement involves raising capital by selling shares to individual or group investors, such as high net worth individuals and venture capital firms.

- Initial Public Offering (IPO): An IPO occurs when a private company offers its shares to the public for the first time to raise funds for product development and to provide returns to early-stage investors. A successful IPO marks a company's transition to being publicly traded.
- Other Equity: This category encompasses various forms of equity investments not classified under the previously mentioned types, as identified during our research.

Figure 15 Funding and Investments Database Glimpse

| Innut E    | and Investment Analysis unding Dataset |                        |                         |                  |      |                            |                                      |                |      |               |
|------------|--|------------------------|-------------------------|------------------|------|----------------------------|--------------------------------------|----------------|------|---------------|
|            | ontents>>                              |                        |                         |                  |      |                            |                                      |                |      |               |
| Date: U.S. | G10010222                              |                        |                         |                  |      |                            |                                      |                |      |               |
|            |  |                        |                         |                  |      |                            |                                      |                |      |               |
| S.No.      | Company Name                           | Headquarters (Country) | Region                  | Month-Year       | Year | Type of Funding            | Funding Amount                       | Funding Amount | Amou | unt (USD Mill |
| 29         | Berry Global                           | US                     | North America           | Jun-21           | 2021 | Private Placement          | USD 1750 million                     | 1750           |      | 1750.0        |
| 17         | Sonoco                                 | US                     | North America           | Jun-21           | 2021 | Debt                       | EUR 750 million                      | 750            |      | 887.1         |
| 20         | Stora Enso                             | Finland                | Europe                  | Dec-21           | 2021 | Debt                       | EUR 700 million                      | 700            |      | 827.9         |
| 12         | O-I Glass                              | US                     | North America           | May-23           | 2023 | Debt                       | USD 682.4 million                    | 682.4          |      | 682.4         |
| 15         | SCHOTT                                 | Germany                | Europe                  | Oct-23           | 2023 | Other Equity               | EUR 14.8 million                     | 14.8           |      | 16.0          |
| 10         | Catalent Pharma                        | US                     | North America           | Oct-23           | 2023 | Debt                       | USD 600 million                      | 600            |      | 600.0         |
| 22         | Stora Enso                             | Finland                | Europe                  | Nov-23           | 2023 | Debt                       | SEK 5.2 billion                      | 5200           |      | 483.6         |
| 19         | Huhtamaki                              | Finland                | Europe                  | Nov-20           | 2020 | Debt                       | EUB 400 million                      | 400            |      | 456.9         |
| 28         | Berry Global                           | US                     | North America           | Jan-20           | 2020 | Private Placement          | EUR 1075 million                     | 1075           |      | 1227.9        |
| 23         | Berry Global                           | US                     | North America           | Jan-24           | 2024 | Private Placement          | USD 800 million                      | 800            |      | 800.0         |
| 26         | Berry Global                           | us                     | North America           | Jan-21           | 2021 | Private Placement          | USD 800 million                      | 800            |      | 800.0         |
| 4          | Gerresheimer                           | Germany                | Europe                  | Nov-20           | 2020 | Debt                       | EUR 325 million                      | 325            |      | 371.2         |
| 9          | Corning                                | US                     | North America           | Jun-20           | 2020 | Grant                      | USD 204 million                      | 204            |      | 204.0         |
| 14         | Billerud                               | Sweden                 | Europe                  | Jan-23           | 2023 | Grant                      | USD 200 million                      | 200            |      | 200.0         |
| 8          | Corning                                | US                     | North America           | Sep-22           | 2022 | Grant                      | USD 103.8 million                    | 103.8          |      | 103.8         |
| 5          | Stevanato                              | Italu                  | Europe                  | Mar-23           | 2023 | Debt                       | EUR 70 million                       | 130            |      | 140.7         |
| 7          | Stevanato                              | Italy                  | Europe                  | Mar-22           | 2022 | Grant                      | USD 95 million                       | 95             |      | 35.0          |
| - 1        | Sanner                                 | Germany                | Europe                  | Oct-21           | 2021 | Other Equity               | Undisclosed                          | Undisclosed    |      | Undisclosed   |
| 16         | SCHOTT                                 | Germany                | Europe                  | Nov-21           | 2021 | Grant                      | EUR 4.5 million                      | 4.5            |      | 5.3           |
| 6          | Stevanato                              | kalu                   | Europe                  | Jul-21           | 2021 | IPO                        | EUR 1.5 million                      | 15             |      | 1.8           |
| 18         | Huhtamaki                              | Finland                | Europe                  | May-23           | 2023 | Debt                       | EUR 125 million                      | 125            |      | 135.3         |
| 25         | Berry Global                           | US                     | North America           | Mar-21           | 2023 | Private Placement          | USD 775 million                      | 775            |      | 775.0         |
| 27         | Berry Global                           | US                     | North America           | Oct-20           | 2020 | Private Placement          | USD 750 million                      | 750            |      | 750.0         |
| 30         | Berry Global                           | US                     | North America           | Mar-23           | 2023 | Private Placement          | USD 500 million                      | 500            |      | 500.0         |
| 24         | Berry Global                           | US                     | North America           | Jun-21           | 2023 | Private Placement          | USD 400 million                      | 400            |      | 400.0         |
| 13         | Billerud                               | Sweden                 | Europe                  | Nov-23           | 2023 | Debt Placement             | EUR 110 million                      | 110            |      | 119.0         |
| 21         | Stora Enso                             | Finland                | Europe                  |                  | 2023 | Debt                       | EUR 500 million                      | 500            |      | 1.1           |
|            |  |                        |                         | May-23           |      | Private Placement          |                                      |                |      | 293.9         |
| 2          | Gerresheimer<br>O-I Glass              | Germany<br>LIS         | Europe<br>North America | Apr-23<br>Dot-21 | 2023 | Private Placement<br>Grant | EUR 271.6 million<br>GBP 500 million | 271.6<br>500   |      | 293.9         |
| — II       | Cover / Note of Confide                |                        |                         | unding Datase    |      |                            | rrency Exd   4                       | 500            | _    | 14            |

Figure 16 Funding and Investments Analysis Glimpse



| sustainable pharmaceu confidentiality reasons. | wever, this inform | ation cannot be d | isclosed due to |
|--|--------------------|-------------------|-----------------|
| v  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |
|  |                    |                   |                 |

## INTERVIEW CONTACT LIST

During the course of the project, I prepared an interview contact list for conducting primary research. A database containing the contact details of relevant people in the particular firm was prepared. The collected data was used for conducting interviews with important stakeholders in this domain. Additionally, we run surveys using these contacts.

Primary research conducted using this information helps us in drawing important insights from the market directly. An example of one such interview contact list has been presented in the table below.

Table 5 Sustainable Packaging Providers: Sample Interview Contact List of Companies

| S. No | Company                      | Name                         | Designation             | Email                                  |
|-------|------------------------------|------------------------------|-------------------------|--|
| 1     | Amcor                        | Ron Delia                    | Chief Executive Officer | ron.delia@amcor.com                    |
| 2     | Aptar                        | Stephan Tanda                | Chief Executive Officer | stephan.tanda@aptar.com                |
| 3     | Ardagh Group                 | Matthew Aston                | Director                | matthew.aston@ardaghgroup.com          |
| 4     | Ardagh Group                 | Paul Coulson                 | CEO                     | paul.coulson@ardaghgroup.com           |
| 5     | Berlin Packaging             | Rick Brandt                  | Chief Executive Officer | rbrandt@berlinpackaging.com            |
| 6     | Berry Global                 | Tom Salmon                   | Chief Executive Officer | tomsalmon@berryglobal.com              |
| 7     | Bormioli Pharma              | Alessandro Gazzotti          | Director                | alessandro.gazzotti@bormiolipharma.com |
| 8     | Bormioli Pharma              | Andrea Lodetti               | CEO                     | andrea.lodetti@bormiolipharma.com      |
| 9     | Bormioli Pharma              | Mauro Gandolfi               | Director                | mauro.gandolfi@bormiolipharma.com      |
| 10    | Bormioli Pharma              | Valerio Agostini             | Director                | valerio.agostini@bormiolipharma.com    |
| 11    | Comar                        | Michael Ruggieri             | Chief Executive Officer | mruggieri@comar.com                    |
| 12    | Constantia<br>Flexibles      | PimVervaat                   | Chief Executive Officer | pim.vervaat@cflex.com                  |
| 13    | Coveris                      | BERNHARD MUMELTER            | Director                | bernhard.mumelter@coveris.com          |
| 14    | Coveris                      | CHRISTIAN KOLARIK            | PRESIDENT               | christian.kolarik@coveris.com          |
| 15    | Coveris                      | DENNIS PATTERSON             | "DENNIS PATTERSON       |  |
| 16    | PRESIDENT LABELS<br>& BOARD" | DENNIS.PATTERSON@coveris.com |                         |  |
| 17    | Coveris                      | JAKOB A. MOSSER              | CEO                     | jakob.mosser@coveris.com               |
| 18    | Coveris                      | MARTIN DAVIS                 | PRESIDENT               | martin.davis@coveris.com               |

| S. No | Company                    | Name                 | Designation                  | Email                                 |
|-------|----------------------------|----------------------|------------------------------|---------------------------------------|
| 19    | Company A                  | Miles Roberts        | Chief Executive Officer      | miles.roberts@dssmith.com             |
| 20    | Ess Dee<br>Aluminium       | Sudip Dutta          | chairman                     | sudipdutta@essdee.in                  |
| 21    | Gerresheimer               | Dietmar Siemssen     | Chief Executive Officer      | dietmar.siemssen@gerresheimer.com     |
| 22    | Hughes<br>Enterprises      | Amy Packer           | Director                     | apacker@hughesent.com                 |
| 23    | Hughes<br>Enterprises      | Steve Hughes         | CEO                          | shughes@hughesent.com                 |
| 24    | Huhtamaki                  | Charles Héaulmé      | CEO                          | charles.heaulme@huhtamaki.com         |
| 25    | Mondi Group                | Andrew King          | Chief Executive Officer      | andrew.king@mondigroup.com            |
| 26    | Origin Pharma<br>Packaging | Tim Pocock           | Chief Executive Officer      | tim.pocock@originltd.com              |
| 27    | Owens Illinois             | Arnaud Aujouannet    | Senior Vice President        | arnaud.aujouannet@o-i.com             |
| 28    | Owens Illinois             | "Andres A. Lopez     |                              |                                       |
| 29    | II                         | CEO                  | Andres.Lopez@o-i.com         |                                       |
| 30    | PaperFoam                  | Damon Kuntz          | Director                     | kuntzd@paperfoam.com                  |
| 31    | PaperFoam                  | Dustin Wills         | Founder and Principal        | willsd@paperfoam.com                  |
| 32    | PaperFoam                  | Philip Bredt         | Vice President               | bredtp@paperfoam.com                  |
| 33    | PaperFoam                  | Roel Groenveld       | General Manager              | groenveldr@paperfoam.com              |
| 34    | PaperFoam                  | Willem Derkman       | Chief Executive Officer      | derkmanw@paperfoam.com                |
| 35    | PGP Glass                  | Mohammedfiroj Shaikh | Assistant General<br>Manager | mohammedfiroj.shaikh@piramalglass.com |
| 36    | PGP Glass                  | Vijay Shah           | CEO                          | vijay.shah@piramalglass.com           |
| 37    | Pharmapac                  | Linda McEnaney       | Director                     | lindamcenaney@pharmapacuk.com         |
| 38    | PKG Packaging              | Craig Swett          | VP Sales                     | c.swett@pkgpackaging.com              |
| 39    | PKG Packaging              | Frank Roughan        | Executive Vice President     | f.roughan@pkgpackaging.com            |
| 40    | ProAmpac.                  | Brent Wise           | Vice President               | brent.wise@proampac.com               |
| 41    | ProAmpac.                  | Eric Daughtry        | Vice President               | eric.daughtry@proampac.com            |
| 42    | ProAmpac.                  | Greg Tucker          | Founder and CEO              | greg.tucker@proampac.com              |
| 43    | ProAmpac.                  | Kelly Lisk           | Chief Executive Officer      | kelly.lisk@proampac.com               |
| 44    | Röchling Group             | Raphael A. Wolfram   | CEO                          | rwolfram@roechling.com                |
| 45    | SANA PACKAGING             | Ron Basak-Smith      | Chief Executive Officer      | ron@sanapackaging.com                 |
| 46    | Schott                     | Dr. Frank Heinricht  | Chief Executive Officer      | frank.heinricht@schott.com            |
| 47    | Sealed Air                 | Angel Shelton Willis | VP,                          | angel.willis@sealedair.com            |
| 48    | Sealed Air                 | Claudia Contini      | Director                     | claudia.contini@sealedair.com         |
| 49    | Sealed Air                 | Emile Chammas        | VP                           | emile.chammas@sealedair.com           |
| 50    | Sealed Air                 | Gerd Wichmann        | PRESIDENT                    | gerd.wichmann@sealedair.com           |
| 51    | Sealed Air                 | Kevin Piccione       | PRESIDENT                    | kevin.piccione@sealedair.com          |
| 52    | Sealed Air                 | Sergio Pupkin        | VP                           | sergio.pupkin@sealedair.com           |
|       |                            |                      |                              |                                       |

| S. No | Company                 | Name                | Designation             | Email                              |
|-------|-------------------------|---------------------|-------------------------|------------------------------------|
| 53    | Sealed Air              | Susan Edwards       | VP                      | susan.edwards@sealedair.com        |
| 54    | Sealed Air              | Ted Doheny          | CEO                     | ted.doheny@sealedair.com           |
| 55    | Sealed Air              | Tobias Grasso       | PRESIDENT               | tobias.grasso@sealedair.com        |
| 56    | SGD Pharma              | Christophe Nicoli   | Chief Executive Officer | christophe.nicoli@sgdgroup.com     |
| 57    | Softbox Systems         | Kevin Valentine     | Chief Executive Officer | kevin.valentine@softboxsystems.com |
| 58    | Sonoco                  | R. Howard Coker     | Chief Executive Officer | howard.coker@sonoco.com            |
| 59    | Stoelzle Glass<br>Group | Artur Woloszyn, MBA | CEO                     | artur.woloszyn@stoelzle.com        |
| 60    | Stoelzle Glass<br>Group | Ewelina Tokarska    | Director                | ewelina.tokarska@stoelzle.com      |
| 61    | Stoelzle Glass<br>Group | Georg Feith         | CEO                     | georg.feith@stoelzle.com           |
| 62    | Swiftpak                | Craig Gulley        | Managing Director       | craig.gulley@swiftpak.co.uk        |
| 63    | Tekni-Plex              | Brenda Chamulak     | Chief Executive Officer | brenda.chamulak@tekni-plex.com     |

#### CONCLUSION

This report provides a brief description of the work done during my internship period. It describes how we initially start working on a report and drafting chapters sourced from the captured information in the database. All these chapters are finally combined to build a client ready document. It outlines the steps involved in creating the report, emphasizing secondary research, data analysis and validation, and the chapters. The individual chapters are consolidated to form a unified document, producing a research report ready for clients that undergoes a quality assurance process to guarantee its excellence.

During my internship period, my primary focus was to work at multiple reports at same time and ensure the quality, accuracy, and effectiveness of content produced. Our team is responsible for the reviewing in order to ensure the quality of the report, guarantee accuracy, presentation, and adherence to the company's standards. Additionally, our responsibilities include proofreading, restructuring, and editing the content created by the writers, optimizing content using SEO guidelines, pitching new ideas, and collaborating with project teams on various projects. Further, I have been actively involved in content creation for digital marketing and organizing various events in the firm.

This internship report contains only the information and content that the company has allowed to reveal for the completion of this report. These 6 months of internship period has enabled me to have a basic understanding on how to work and prepare a business research report, along with the roles and responsibilities of a business analyst.

#### References

- 1. Knowledgeridge.com. [Online]. Available: https://www.knowledgeridge.com/expert-views/transforming-pharmaceutical-andmedical-device-primary-packaging-forsustainability#:~:text=Pharmaceutical%20And%20Medical%20Device%20Primary%. [Accessed: 06-Jun-2024].
- 2. I. D. Ibrahim et al., "Need for sustainable packaging: An overview," Polymers (Basel), vol. 14, no. 20, p. 4430, 2022.
- 3. F. Bassani, C. Rodrigues, and F. Freire, "Life cycle assessment of pharmaceutical packaging addressing end-of-life alternatives," Waste Manag., vol. 175, pp. 1–11, 2024.
- 4. S. Moore, "Biodegradable and sustainable plastic alternatives in pharmaceutical packaging," AZoM, 01-Feb-2021. [Online]. Available: https://www.azom.com/article.aspx?ArticleID=20060. [Accessed: 06-Jun-2024].
- 5. S. Mittal, B. Wadhwani, and M. Lakhani, "Innovations in Pharma Packaging Technologies," J. Young Pharm., vol. 13, no. 3, pp. 197–200, 2021.
- 6. "No title," Blueprintautomation.com. [Online]. Available: https://blueprintautomation.com/en/event/the-importance-of-packaging-in-thepharmaceutical-industry. [Accessed: 06-Jun-2024].
- 7. "Jul-sep 2023 volume 7 issue 3 : Matrix science pharma," Lww.com. [Online]. Available: https://journals.lww.com/mtsp/fulltext/2023/07030/a\_step\_toward\_sustainability\_\_a\_r . [Accessed: 06-Jun-2024].
- 8. Lubrizolcdmo.com. [Online]. Available: https://lubrizolcdmo.com/blog/aseptic-manufacturing-and-sterile-fill-finish-forcomplex-drug-products/. [Accessed: 06-Jun-2024].
- 9. T. Boomsma, "Pharmaceutical Packaging Types & Benefits (updated 2023)," Swiftpak, 05-Oct-2023.
- 10. Polypouch.co.uk. [Online]. Available: https://www.polypouch.co.uk/news/pharmaceutical-packaging-types-benefits/. [Accessed: 06-Jun-2024].
- 11. Meghmaniglobal.com. [Online]. Available: https://www.meghmaniglobal.com/what-are-the-different-types-of-pharmaceuticalpackaging/. [Accessed: 06-Jun-2024].
- 12. Swiftpak.co.uk. [Online]. Available: https://www.swiftpak.co.uk/insights/pharmaceutical-packaging-types-andbenefits#:~:text=Common%20types%20of%20primary%20pharmaceutical,and%2 0w. [Accessed: 06-Jun-2024].
- 13. Ecobliss-pharma.com. [Online]. Available: https://www.ecobliss-pharma.com/blog/pharmaceutical-primary-secondary-tertiarypackaging. [Accessed: 06-Jun-2024].
- 14. I. D. Ibrahim et al., "Need for sustainable packaging: An overview," Polymers (Basel), vol. 14, no. 20, p. 4430, 2022.

- 15. "Plastic vs paper packaging: The pros and cons," Swiftpak. [Online]. Available: https://www.swiftpak.co.uk/insights/plastic-vs-paper-packaging-the-pros-and-cons. [Accessed: 06-Jun-2024].
- 16. "Sustainable pharmaceutical packaging," Origin Pharma Packaging, 21-Jun-2018. [Online]. Available: https://www.originltd.com/packaging-design/sustainable-pharmaceutical-packaging/. [Accessed: 06-Jun-2024].
- 17. OriginItd.com. [Online]. Available: https://www.originItd.com/packagingdesign/sustainablepharmaceuticalpackaging/#:~:text=Sustainable%20packaging%20is%20designed%20. [Accessed: 06-Jun-2024].
- 18. News-medical.net. [Online]. Available: https://www.news-medical.net/life-sciences/How-is-Sustainability-Incorporated-intoPharmaceutical-Packaging.aspx. [Accessed: 06-Jun-2024].
- 19. "Review on: THE PHARMACEUTICAL PACKAGING," PharmaTutor. [Online]. Available: https://www.pharmatutor.org/articles/the-pharmaceutical-packaging-article. [Accessed: 06-Jun-2024].
- 20. J. Clifton, "Why ISO standards are important in the packaging industry," Packaging Strategies, 20-Sep-2019. [Online]. Available: https://www.packagingstrategies.com/articles/95098-why-iso-standards-are-soimportant-in-the-packaging-industry. [Accessed: 06-Jun-2024].
- 21. "Envoy solutions," Hughesent.com. [Online]. Available: https://www.hughesent.com/blog/4-advantages-of-eco-friendly-packaging/. [Accessed: 06-Jun-2024].
- 22. "Discover thousands of collaborative articles on 2500+ skills," Linkedin.com. [Online]. Available: https://www.linkedin.com/pulse/top-5-benefits-sustainable-packaging-your-businessvic-ning-rperc/. [Accessed: 06-Jun-2024].
- 23. M. Kaur, "The pros and cons of Eco-friendly packaging," LeKAC, 19-Nov-2020. [Online]. Available: https://lekac.com/production/the-pros-and-cons-of-eco-friendly-packaging. [Accessed: 06-Jun-2024].
- 24. Farmersreviewafrica.com. [Online]. Available: https://farmersreviewafrica.com/biodegradable-and-sustainable-packagingalternatives-to-drive-the-sugarcane-packaging-market-to-us-889-0-million-by-2033/. [Accessed: 06-Jun-2024].